The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

I believe it's time healthcare delivery leverages the technological innovations that have rapidly redefined how the retail ...

Weight loss platform Noom launched a full-page print ad in The Wall Street Journal this week, calling on policymakers to create new guidance around expensive drugs, as compounded GLP-1s are set to be ...

Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

In an interview with Futurism, veteran psychiatrist and ADHD specialist William Dodson revealed that prescribers in the know ...

As the U.S. stock market navigates through a period of volatility driven by tariff news and economic data, major indexes like the Dow Jones, S&P 500, and Nasdaq Composite are showing resilience with ...

In a week marked by significant market volatility, with the Dow Jones and Nasdaq experiencing sharp declines following recent tariff announcements, investors are keenly observing growth companies that ...

Barclays lowered the firm’s price target on Autodesk (ADSK) to $325 from $365 and keeps an Overweight rating on the shares after meeting with ...

In a report released today, Saket Kalia from Barclays maintained a Buy rating on Autodesk (ADSK – Research Report), with a price target of ...

Eli Lilly (NYSE:LLY) announced that its financial results for Q1 2025, prepared under the U.S. generally accepted accounting ...